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ABSTRACT 
 
BACKGROUND Until recent years, uptake of voluntary counselling and testing for HIV 
(VCT) and enrolment into the programme of prevention of mother-to-child transmission 
of HIV (PMTCT) was very poor among pregnant women. This study aims to identify 
factors influencing enrolment into the programme of PMTCT among post-partum 
women.  
 
METHODS Cross sectional interview of 200 consecutive post-partum women was 
conducted using an interviewer-administered questionnaire. Forms of those who declined 
to participate were kept and marked “refusal”. Data was analysed using Epi info 
software. 
 
RESULTS The response rate was 84.5%. VCT uptake was 96.9% among participants 
and PMTCT uptake among HIV+ve mothers was 90.9%. The mean age of participants 
was 25 years, ranged from 14 to 41 years. Women in the age-group 20-29 were more 
likely to accept VCT and enroll for PMTCT than women in the other age-groups 
(p=0.0114). 
 
CONCLUSIONS AND RECOMMENDATIONS Provision of clear and well-defined 
policy guidelines and strong commitment to implementation of these guidelines have 
been largely responsible for impressive uptake of VCT among participants and high rates 
of satisfaction with PMTCT programme among HIV-infected women.  Training of more 
lay-counsellors is recommended for its cost-effectiveness.                                                      
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 CHAPTER 1 
 
INTRODUCTION 
The efficacy of the programmes of prevention of mother to child transmission of HIV 
(PMTCT), described in many studies across the globe, has offered relief to many of these 
countries which have been ravaged by HIV/AIDS, and indeed to the whole world. 
 
The HIV epidemic in the paediatric population has reached alarmingly high rates and 
mother-to-child transmission of HIV (MTCT) is the main mode of spread of HIV in this 
‘innocent’ population1,2,3. It is estimated that, to date, 5.1 million children worldwide have 
been infected by HIV4. The innocence of the unborn child justifies everything that could 
be done to prevent its acquisition of the deadly virus and guarantee its ‘rights to life, 
survival and development’.5    
 
HIV/AIDS is a major cause of infant and childhood morbidity and mortality in Africa. In 
children under 5 years of age, HIV/AIDS now accounts for a rise of more than 19% in 
infant mortality, and a 36% rise in under-5 mortality6, since its earliest days in the 80s’. 
 
 Yet for the most part, HIV in children is preventable. In industrialised countries of North 
America and Europe, paediatric HIV has largely been controlled. In these settings, HIV 
testing as part of routine antenatal care, combinations of antiretroviral (ARV) drug 
regimens, elective caesarean section, and complete avoidance of breastfeeding have 
translated into mother-to-child transmission of less than 2%6. International and local 
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 experience has shown that the provision of antiretroviral chemoprophylaxis and 
replacement feeding can cause a dramatic reduction in the risk of transmission from 
mother to infant in resource-constrained settings.7-12 
 
More than 95% of HIV-infected infants in Africa acquire HIV from their mothers during 
pregnancy, at the time of delivery, or postnatally through breastfeeding1. The 
transmission risk for a child born to an HIV-infected mother in an African setting without 
interventions for PMTCT is about 30-40%6. In South Africa, the risk of vertical 
transmission from HIV-infected mothers to their infants is estimated to be between 19% 
and 36%, depending on whether or not the child is breastfed13. 
 
The use of antiretroviral therapy (ART) represents the first major breakthrough in the 
PMTCT and to date ART is the most important strategy to prevent MTCT of HIV.  Since 
the potent effects of Zidovudine (AZT) in reducing the risk of vertical transmission were 
first published in 199411 ,  numerous studies have confirmed this effect and have shown 
similar effects using other antiretroviral drugs including Lamivudine (3TC), Didanosine 
(ddI), Nevirapine (NVP) and Stavudine (d4T), as monotherapy or in combination. The 
added advantage of Highly Active Antiretroviral Therapy (HAART) for PMTCT has also 
been established. Effective short courses of ART regimens for PMTCT include: (1) 
Nevirapine 200mg given to the mother at onset of labour and 2mg/kg single dose to the 
infant within 1 week (HIVNET012) and preferably within 72hours. (2) Short course AZT 
Regimen (Modified Thai) which gives oral AZT 300mg every 12hours from 32-34 weeks 
gestation during pregnancy and every 3 hours in labour; and for 1week to the infant, 
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 4mg/kg/day every 12hours. (3) PHPT-2 Regimen (2004 Thai Regimen) which combines 
AZT (starting at 28 weeks or as soon as possible thereafter) with single dose of maternal 
and infant Nevirapine (HIVNET 012). The current South African PMTCT protocol is 
basically the Thai Regimen and modified Thai Regimen with little adjustments to the 
infant ARV regimen for optimal effectiveness, depending on when the pregnant woman 
was started on ARV. Table 1.1 below shows a detailed summary of the PMTCT 
Antiretroviral protocols for pregnant women and infants.  
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 Table 1.1 South African Antiretroviral Protocols for pregnant women and infants 
CLINICAL DECISION REGIMEN FOR WOMAN REGIMEN FOR INFANT 
PMTCT regimen for ALL groups of women from 28 weeks of pregnancy unless already on HAART 
CD4 cell count >200, continue 
with this PMTCT regimen 
 
CD4 count ≤200, continue AZT 
up to point HAART initiated 
 
 
• AZT started from 28 weeks 
onwards  AND 
• sdNVP + AZT at onset of 
labour on a 3-hourly basis 
• If in false labour, continue 
with AZT 
sdNVP + AZT for 7 days* 
 
AZT for 28 days if: 
• Mother received <4weeks 
AZT during pregnancy 
• Mother received <4 weeks 
HAART or  
• Mother only received sdNVP 
 
HAART regimens (1a and 1b). If on AZT as above need to switch to regimens below  
CD4 cell count ≤200 or WHO 
stage IV group 
 
• d4T + 3TC + NVP (Regimen 
1b) preferred regimen for 
pregnant women. Begin at 
any age 
• d4T +3TC + EFV (Regimen 
1a) For pregnant women on 
regimen 1a, switch 1b in the 
first trimester. 
• If presenting after first 
trimester, continue regimen 
1a. 
• Continue through labour, 
delivery and postnatal 
periods. 
• After the first trimester, if 
women develop NVP-
associated toxicity, then 
NVP should be substituted 
with EFV 
 
sdNVP + AZT for 7 days*     
 
AZT for 28 days if   
  
• Mother received <4weeks 
HAART  
 
Unbooked woman presents in 
labour 
Also includes women of known 
status who have had no ARVs 
during pregnancy. Do not require 
testing 
 
Consent and test for HIV only in 
stage 1 labour.  
If advanced stage of labour, defer 
maternal testing till after delivery. 
If HIV positive 
• sdNVP + AZT at onset of 
labour and on AZT at 3-
hourly basis 
 
If she is in false labour, continue 
with AZT.  
 
sdNVP + AZT for 28 days 
 
(Adapted from Policy and Guidelines for the implementation of the PMTCT programme. National 
Department of Health. 11 February 2008) 
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 A 4-pronged approach has been suggested for PMTCT of HIV (by UN/WHO). 
(1) Primary prevention; (2) Prevention of unintended pregnancies in HIV-infected 
women; (3) PMTCT of HIV; (4) Provision of care and support for HIV-infected 
women, their infants, and their families.   
 
PMTCT efforts to date have focused almost exclusively on preventing transmission 
after an HIV-positive woman is already pregnant. 
 
Specific interventions of PMTCT include: 
1. Use of ARV drugs. 
2. Safer delivery practices. 
3. Infant feeding. 
4. Counselling. 
5. Support. 
 
Despite the UNGASS target, in 2005 only 15% of HIV-infected pregnant women 
received preventive drugs – barely making a dent in the number of infant infections. In 
2006 the proportion was 23%.14  
The results had been so poor that they prompted an unusually frank admission from a 
senior United Nations official in August 2006:  
“These programmes have been a failure. Despite the fact that the global HIV response is 
now awash in funding, pregnant women still don’t have access to the drugs that will 
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 prevent them from passing the virus on to their children.” - Dr. Arletty Pinel, Chief of 
UNFPA Reproductive Health Branch 15 
 
The main challenges of implementing PMTCT programmes in the sub-Saharan African 
region had been identified as low uptake of HIV testing by antenatal women, and low 
uptake of ART by HIV-positive women identified during pregnancy; and these in turn 
attributed to institutional factors (such as client flow and low staff levels) and inadequate 
community engagement (especially from male partners)16. 
 
The literature is scanty on why pregnant women generally do not embrace VCT, and why 
the HIV-infected women identified during antenatal care are reluctant to enrol for the 
PMTCT programmes. The precarious socio-economic situation of the populations in 
developing countries, and underdeveloped health structures and services has been 
identified as some of the obstacles to acceptance of PMTCT among pregnant women. “In 
addition anxiety and reluctance of general population in the face of HIV problem and the 
prevalence of maternal anaemia reduce the acceptability and safety of AZT treatment for 
pregnant women in developing regions3.”   
 
A study in the Khayelitsha district of Western Cape17 demonstrated the feasibility and 
effectiveness of a PMTCT programme within busy routine obstetric services in urban 
primary health care settings. This study attributed the effectiveness of the programme to 
high rates of acceptance for testing and subsequent enrolment into the programme. 
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 1.1 Statement of the problem 
The researcher has witnessed poor uptake of PMTCT programme arising from denial and 
apathy to outright rejection of the programme, in various clinical settings from Lesotho to 
South Africa, and had wondered where the problem lay. Is it with the health institutions, 
the environment or with the patients themselves?  
The researcher therefore attempts to study the problem from the patients’ perspective so 
as to enrich our current knowledge and possibly improve our approach to solving the 
problem. 
 
1.2 Justification for study 
 
Medicine is changing from prescriptive to collaborative practice. General Practitioners 
have to do more talking, listening, and generally understanding and carrying the patient 
along in all aspects of patient’s care, than used to be. These are the needed ingredients for 
the changing role of General Practitioners from predominantly curative and paternalistic 
stance to more of preventive, promotive and rehabilitative care through collaborative 
approach. 
 
What the researcher had learnt in Family Medicine in the last 3 years can be summarised 
as ‘prevention, no doubt, is better than cure’. 
 
To date, there is no known cure for HIV/AIDS, and the best we can do is to help prevent 
it. The good thing is that it is preventable. The efficacy of the PMTCT programmes 
described in many studies across the globe is also cheering news in the care of the 
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 innocent paediatric population, but the problem is the complex nature of human beings, 
patients and health care workers inclusive. 
 
For those of us who are in position to know our right from left, good from bad, the choice 
is entirely that of the individual and we have the right to choose between life and death, 
health or disease in spite of all that the health care systems may offer us to make a 
healthy choice. But what about the unborn child who is not so privileged and whose 
rights to life, survival and development are determined by others?  For this reason, some 
severely HIV-ravaged countries have taken bold steps to protect the innocent child by 
making it compulsory for pregnant women to go through PMTCT programmes. 
 
The researcher  has witnessed low uptake of this laudable programme, read about it, and 
believed this to be the prevailing situation in most countries in Africa. 
 
It is also believed that the problem is either with the clients (individual), the environment 
(social), or the health care system (institutional factors), or a combination of  these in 
varying degrees. Pregnant women are the ones at the very centre of the programme. They 
would be expected to recall some of the factors that influenced their acceptance of VCT 
and subsequent enrolment into the PMTCT where indicated. Post-partum women have 
been chosen for this study so that even those who entered the programme very late 
(including the unbooked, presenting in labour) could also be accommodated in the study. 
The South African PMTCT protocols have provisions for every pregnant mother up to 
immediately after delivery, to enter into the programme (see summary on Table 1.1)    
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 The protocol for this study was prepared in 2006 with a background experience of the 
researcher in the previous years, of low uptake of VCT and PMTCT but at the end of the 
study in 2008, a lot of improvement was noted. As well as identifying factors hindering 
enrolment into the programme, this study also highlights some factors that have 
facilitated the improvement recorded. Together, these are the factors influencing 
enrolment into the PMTCT programme which this study aimed to identify. 
 
 
 
1.3 Aim                                                                                                                                                                 
The aim of this study was to identify factors influencing enrolment into the programme of 
prevention of mother-to-child transmission of HIV (PMTCT) among postnatal women. 
 
1.4 Objectives of the study 
The objectives of the study in the study population were: 
a). To determine the demography of respondents. 
b). To determine the knowledge, attitude, beliefs and practice of PMTCT among the 
respondents.  
c). To identify retrospectively, factors (institutional, patient-related, environmental and 
others) which influenced uptake of VCT, among postnatal women. 
d). To identify factors (institutional, patient-related, environmental and others) which 
influenced subsequent enrolment into the PMTCT programme during their pregnancy 
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 e). To determine the relationship between the variables mentioned above.  
 
1.5 Definitions:  The following definitions apply in this report. 
Prevention of mother-to-child transmission of HIV: - includes all interventions aimed 
ultimately at reducing or eliminating the risk of transmission of the HIV from a mother to 
her child at different stages of pregnancy, delivery and postnatally, during breastfeeding. 
These involve primary prevention of HIV among women of child bearing age; prevention 
of unintended pregnancies among HIV-infected women; prevention of transmission of 
HIV from infected pregnant woman to her baby in-utero and during breast-feeding; and 
provision of care and support to HIV-infected women, their infants and their family, as 
recommended by the WHO.  
Mother-to-child transmission: Transmission of HIV from an HIV-positive woman 
during pregnancy, delivery or breastfeeding to her child. This term is used because the 
immediate source of the infection is the mother, and does not imply blame on the mother. 
Post-partum period: Period from immediately after the birth of the baby to 42 weeks 
after. This term has been used inter-changeably with post-natal period 
 
Institutions: refer to various health facilities- the clinics and the hospitals in particular. 
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 CHAPTER 2 
LITERATURE REVIEW 
 
Worldwide, more than two million HIV-infected women give birth annually, but only 9% 
of them receive PMTCT intervention18. It was expected that having in place a simple 
PMTCT programme that provides ARV prophylaxis for HIV-infected mothers and 
children could increase the utilization of these services. However studies from both 
developed19 and developing countries20-22 have proven that the services were underused. 
 
PMTCT is a politically and scientifically accepted approach to reduce the impact of HIV, 
especially on the children. In South Africa, PMTCT programme suffered a political 
setback until the Constitutional Court ruled in 2002 in favour of ARV roll out, against 
government’s position then. South Africa is home to at least 5.6million people living with 
HIV (PLWH); at 11% has one of the highest population prevalence rates in the World 
(Dorrington, Johnson, Bradshaw and Daniel, 2006)23. Despite South Africa’s high HIV 
prevalence rate the national government   prevaricated on provision of ARVs for 
PMTCT22, until after the court’s ruling in 2002. Government cited economic reasons and 
concerns about side-effects of ARV for its position. Since then, the commitment of the 
government following the results of the pilot studies has brought about improvements in 
the national PMTCT programme. 
 
“There are approximately 1million births per calendar year24. Based on antenatal 
statistics, the estimated number of HIV positive pregnant women in 2006 was 302,000 
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 (30.2%) and 290,000 (29.0%) in 200724. The total number of HIV positive pregnant 
women identified and enrolled into the PMTCT programme in 2006 was 186,646 
(72.7%)”.24 
 
In the review of PMTCT uptake among South African Provinces, Limpopo had PMTCT 
uptake rate of 55% in 2006 and 62% in 2007 among HIV positive pregnant women. The 
highest rate was observed in the Western Cape, being 90%, in the two years24.  In this 
study site, monthly antenatal HIV prevalence among pregnant women ranged from 11.1% 
to 39.5 % in the previous 12 months with an average of 28%. 
 
 Various studies17,25-27 have demonstrated the effectiveness and feasibility of the PMTCT 
programme but there still exist a number of factors hindering the uptake of VCT (entry 
point to PMTCT), and enrolment into the PMTCT programme. A 3-dimensional view 
was taken of  these obstacles viz – patient-related factors, institutional factors, and the 
environment or community factors. 
 
PMTCT involves, or should involve every would-be mother. For many, (HIV-negative), 
it starts and ends with a 2nd VCT after the window period. Others have to go through the 
programme from VCT till probably 18 months after delivery when the outcome of the 
intervention can safely be verified. Mothers are expected to have a good knowledge of 
the programme. Knowledge is power. A good knowledge of the processes and expected 
outcome has empowered many of the participants in this study to take a bold step in 
accepting VCT and those who tested positive going ahead to enrol into the PMTCT 
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 programme against all odds. “In multivariate analysis, factors associated with having an 
HIV test included being interviewed at an urban site, having a high PMTCT knowledge 
score, knowing someone receiving PMTCT or ART and having a partner who had been 
tested for HIV”27 
 
In various settings25-28 acceptance of VCT and subsequent enrolment into the PMTCT 
where necessary, have improved in the last 5 years from around 30-40% to between 
70and 80% on the average. In South Africa which has the largest PMTCT programme in 
Africa29, “close to 2.2million pregnant women have utilized the service in the last 4 years 
with testing uptake rates averaging 70%. Almost 60% of identified HIV positive women 
have received nevirapine”.  The researcher set off in 2006 with the protocol for this study 
with his experience, in the previous years, of low uptake of VCT and PMTCT but at the 
end of the study in 2008, found out there had been a lot of improvement. Similar 
improvements have been recorded in many studies27-28. As well as identifying factors 
hindering enrolment into the programme, this study also highlights some factors that have 
facilitated the improvement recorded. Together, these are the factors influencing 
enrolment into the PMTCT programme which this study aimed to identify. 
 
Health institutions implementing government policies and guidelines on PMTCT have 
made the most contribution towards the improvement in VCT uptake and enrolment into 
the PMTCT programme. Participants in this study and other studies21,26,27 alluded to this. 
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 The social stigma in the patients’ environment or community represents the major 
obstacle to uptake of VCT and enrolment into PMTCT programme. This factor of fear of 
stigma and discrimination by the society cut across all studies on HIV and PMTCT. 
“Many women told the authors that fear of stigma and discrimination was the most 
important barrier for them to use HIV testing services”30  
 
People in the community and partners of participants in this study generally contributed 
negatively by way of stigma and discrimination or apathy towards the HIV positive 
women. Most of the families were dysfunctional with the woman having no support from 
the partner. Thus the decision to take an HIV testing and enrol into the PMTCT 
programme was solely that of the pregnant woman in the majority of participants in this 
study. 
In a study in Uganda by Bajunirwe and Mizoora31 the strongest predictor of willingness 
to accept an HIV test and join the PMTCT programme was the woman’s perception that 
her husband would approve of her testing for HIV. “In Francistown, Botswana, 
approximately 40% of pregnant women are HIV positive. PMTCT has been available 
since 1999, ARV therapy since 2001, and 95% of women have ANC and deliver in the 
hospital. However in 2002 only 33% of ANC clients tested for HIV. Neither fear of 
stigma nor resistance from partners were frequent reasons for refusing an HIV test.”27 
Lack of awareness of the PMTCT programme was the main reason cited. 
 
 The contribution of mass media is also acknowledged in this study as have other 
studies31,32. In a retrospective study of local language radio programme32 – The 
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 Abstinence Be faithful for Youth (ABY), in Uganda, all the VCT records reviewed in all 
three health centres, showed an increase in number of VCT clients from 777 between 
November 2004 and August 2005 to 915 between September 2005 and August 2006. A 
year on year increase of 15%. PMTCT records showed an increase from 520 to 1542 
during the same period. Service providers attributed the increase to the ABY programme. 
“The radio programme helped to remove the fear of testing. You know people naturally 
used to fear testing for HIV” concluded the officer in charge of PMTCT in Kapchorwa 
hospital. 
 
As a result of the negative influence of the community the decision to have VCT and 
enrol in the PMTCT programme became largely personal- that of the individual 
participant, depending on how well informed she was and how well she could use her 
informed position to her own advantage. 
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 CHAPTER 3 
METHODS 
3.1 Introduction  
The aim of this chapter is to describe the methods used in the collection of the data. The 
chapter will include a description of the study design and the site of the study and the 
study population. It includes a description of the sampling method and the actual process 
of data collection. A description of the pilot study has been included. Ethical clearance is 
also discussed. 
  
3.2 Study Design 
This was a cross-sectional descriptive study. 
 
3.3 Site of study  
This study was conducted in the maternity ward of a secondary level hospital in a rural 
area of the Limpopo province, South Africa.  The actual name of the hospital has been 
kept confidential for ethical reasons. High risks patients from about 12 feeder clinics and 
complicated deliveries from these clinics and surrounding hospitals were referred to this 
hospital, which also had a neonatal unit. Monthly antenatal HIV prevalence in the 
previous 12 months varied from 11.1% to 39.5% with an average of 28.5%. Nursing 
Sisters, some with advanced midwifery offered and provided VCT and PMTCT in the 
centre. All had undergone VCT and PMTCT training and ongoing refresher training. 
 Lay counsellors were utilised in the clinics for voluntary counselling while the sisters 
pricked the patients. The lay counsellors too had undergone VCT training and ongoing 
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 refresher training. Rapid HIV test algorithm was used. First response test results were 
confirmed with ACON HIV 1/2/0. Found highly consistent, sisters could not recall the 
last time they had to resort to ELISA confirmatory test. 
Basically a rural setting, the antiretroviral used were still as in the National PMTCT 
protocol, the dual therapy for those not already on HAART.  
 
3.4 Study population  
Antenatal attendees of about 12 clinics around the hospital who were referred to the 
hospital for delivery or for assessment immediately post delivery in the clinic. An 
average of between 250 and 300 deliveries were taken in the maternity centre every 
month. 
 
3.5 Sampling 
3.5.1 Sampling method:-  
A statistician had been consulted and it was recommended that consecutive post-partum 
women, who have just been delivered, shortly before being discharged, should be 
approached for the interview until 200 patients had been approached. Informed consent 
was obtained after adequate information had been given to the participant using a 
standard introductory format - The participants’ information sheet (See Appendix 2). 
Two hundred consecutive post-partum women were approached.  
Those who consented were interviewed. Forms of those who declined were kept blank 
and marked as “refusal”.  
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3.5.2 Sample size:- Two hundred consecutive postnatal women, as per Statistician’s 
recommendation, were approached for interview.  Based on approximately 30% national 
prevalence rate of HIV among pregnant women29  and estimated response rate of at least 
75%, it was hoped that about 50 HIV-positive women would respond and this would 
make for a good analysis. This sample estimate is expected to be within 5-10% of the 
study population, with a 95% confidence interval.  
A response rate of 80% was earlier recorded at the pilot to this study. 
 
 
3.6 Data collection 
 Data collection began on 21 July 2008, and stopped with the 200th patient on 20th August 
2008. A semi-structured interviewer-administered questionnaire designed in English and 
translated into the 2 local languages (Sotho and Xonga) was used for data collection. The 
validity of the measuring instrument had been improved upon by back-translating into 
English language by 2 different sets of translators to ensure consistency. A nurse was 
identified, briefed on the research objectives and trained on the use of the questionnaire to 
obtain accurate data in a consistent manner.  
 
Each participant was asked to confirm the language she preferred (most speak the 2). She 
would then be given a copy of the introductory format (in her language), which 
introduced the researcher and the Nurse translator, the purpose of the study, and formal 
invitation to voluntarily participate. She was then invited into a private room in the post-
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 natal ward, where we established rapport and sought her informed consent verbally and in 
writing. Those who declined were reassured of their right to do so and their forms kept 
blank and marked ‘refusal’. The Researcher administered the questionnaire with the 
English version, to those who gave consent. The Nurse/translator with a relevant copy of 
the translated questionnaire, assisted when and where necessary. Those who needed 
counselling by the Psychologist were referred to her after the interview session. Some 
were ruffled by the interview especially those who tested and enrolled without their 
partners’ knowledge or against their partners’ wish as in a particular participant.  
 
 
3.6.1 Measuring Instrument/Tool: Semi-structured interviewer-administered 
questionnaire designed in English, translated into the two local languages - Sotho and 
Xonga, and back-translated to English. (See Appendix 1). Translations and back-
translations were done (vice-versa) by 2 doctor colleagues and 2 nurse translators who 
were indigenes and were working in the community. 
 
3.6.2. Inclusion criteria: All post-partum women booked and unbooked, who delivered 
in the maternity irrespective of age, parity, and mode of delivery were included in the 
study.  
 
3.6.3 Exclusion criteria: Criteria for exclusion were those with stillbirths or early 
neonatal deaths, non-English speaking or non-speakers of any of the 2 major languages –
Sotho and Xonga. Those with serious obstetric complications e.g. eclampsia and 
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 psychiatric patients who were either depressed or mentally incompetent were also 
excluded in the study. 
 
3.6.4 Data entry & analysis Data was entered and analysed using the Epi info soft ware. 
Student t-test and chi square statistics were used to determine the relationship between 
the demographic variables and uptake of VCT as well as enrolment into the PMTCT 
programme.  The significant p-value of <0.05 was used for the analysis.   
 
 
3.7 Pilot study 
A pilot study was done in another hospital 4 months before the main study to test the 
usefulness of the measuring tool and practicality of data collection and analysis. 
Participants understood the questions very well and were pleased with the explanations in 
the participants’ information sheet (see appendix 2) inviting them to participate in the 
study. We interviewed 10 patients and only two refused to participate, giving a response 
rate of 80%. Two of the eight who participated had no knowledge of PMTCT and were 
not interviewed further on the subject. Of the remaining six only one was HIV-infected 
and was enrolled in the PMTCT programme. She cited the safety of her unborn baby as 
her reason for enrolment. The remaining five tested negative. Awareness of PMTCT 
programme was high among respondents, six out of eight or 75%. 
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 3.8 Ethics 
Approval for this study was obtained from the Human Research Ethics Committee 
(Medical) of the University of the Witwatersrand, Johannesburg. Ethics clearance number 
is - M060726 (see appendix 3) 
Approval of the Postgraduate Committee of the Faculty of Health Sciences Medical 
School was also obtained. (see appendix 4) 
The protocol for this study also got the approval of the Ethics clearance Committee of the 
University of Limpopo on behalf of the Provincial Government. Ethics clearance number 
is - 012/2008 (appendix 5). 
 Finally, the approval for the study was given by the Provincial Government. Ref: 4/2/2 – 
(appendix 6) 
 
Permission was given by the institutions where studies were carried out following 
approval by the Provincial Government. 
Informed consent was obtained of participants based on participants’ information sheet 
accompanying the questionnaire (appendix 2) 
Questionnaires were anonymous and information gathered was kept confidential. 
The identity of the study institutions was kept confidential as promised the participants. 
A clinical Psychologist was arranged earlier on to attend to participants who might need 
further counselling.  
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 3.9 Limitations of this study Information bias might still be inherent in this study as 
with any third party interview involving an interpreter. Either the interpreter still, had 
modified the question to make it friendlier or the interviewee withheld some information 
simply because of the presence of the third party. Confidential information as sensitive as 
one’s HIV status are better divulged on one-on-one basis than with the presence of a third 
party.  
 
There could also have been selection bias as the participants in this study were selected 
“high risk” patients and those with complications who were referred to this secondary 
level hospital for management. The participants therefore did not represent the broad 
spectrum of antenatal attendees from the various primary care levels. 
 
 
3.10 Conclusion 
In summary this chapter included a description of study design, site of study and the 
study population. It described the sample size methods of sampling and data collection 
and analysis. A description of the pilot study, ethical issues and study limitations were 
also discussed. 
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 CHAPTER 4 
RESULTS 
 
4.1 Response rate  
A total of 200 post-partum women were invited to participate in the study. Of these, 169 
agreed to participate giving a response rate of 84.5%.  31, (15.5%) of these women 
refused to participate in the study.  
 
4.2 Demographic information 
The demographic characteristics of the study participants were as presented on Table 4.1. 
The mean age of pregnant women who participated in the study was 25 years, ranged 
from 14 to 41 years. Fifty-one percent of these women were in the age group 20 to 29 
years.  
 
Ninety-eight percent attended antenatal care. Sixty-four percent were single, 53% lived 
with a partner. Forty-nine percent of these women said this was their first pregnancy. 
About 22% said they had experienced miscarriage in their life time. The majority (84%) 
had secondary education. 60% had a household income of less than R2500-00 with only 
5% having household income above R5000.00. 
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 Table4.1: Demographic information 
 No % 
Age (yrs)     (mean ±sd) 25 ± 6.7 (range: 14 to 41) 
<20 33 19.5 
20-29 86 50.9 
30-39 45 26.6 
≥40  5  2.9 
 
Attended Ante natal care  
 
 
 
 
Yes 165      97.6    
No   4       2.4 
 
Marital Status  
 
 
 
  
Single 108       
      36.1  
63.9 
Married  61 
   
Live with partner   
Yes 90 53.3 
No 79 49.7 
  
No of babies before this    
                            
 (range: 0 to 5)         
 
                           None 83 49.1 
1-2 68 40.2 
>2 18 10.7 
 
Miscarriage 
 
 
 
 
Yes  21 12.4 
No 148 87.6 
 
 
 
Level of Education  
None   3 1.7 
Primary  15 8.9 
Secondary 142 84.0 
Tertiary   9 5.3 
  
Household income   
None  35 20.7 
<R2500 101 59.8 
R2500-R5000  23 13.6 
>R5000  10 5.9 
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4.3 Knowledge of Prevention of Mother to Child Transmission of HIV 
The study participants were asked whether they were aware of Prevention of Mother to 
Child Transmission of HIV programme. 161 (95.2%) of these pregnant women said they 
were aware of the programme. Eight (4.7%) of the participants said they were not aware 
of the programme and they were not interviewed further, and so data on VCT and 
PMTCT were not collected for these eight participants. Of those who said they were 
aware of the programme, 93.7% got the knowledge of PMTCT programme from health 
workers. 63.6% others got additional information from the mass media. More than 70% 
of the pregnant women indicated that they knew the contents of the program, except 
knowledge about timing of medication (Table 4.2). 
  
Table 4.2: Knowledge of PMTCT of HIV 
 No % 
Aware of PMTCT   
Yes 161 95.2 
No    8   4.7 
   
Source of knowledge    
            (a)  Nurse/Doctor only    151 93.7 
            (b) Nurse /doctor   +   TV/Radio/Newspaper 96 59.6 
            (c)  Nurse /doctor + School (love life)   16  09.9 
           (d)  partner or friend             02        1.2 
   
What do you know about the programme?   
VCT 161 95.3 
Enrolment of HIV +ve mother 148 87.6 
Medication for mother & child 153 90.5 
Timing of medication   86 50.9 
Testing of the child at certain age 127 75.2 
Follow up of mother and child 137 81.1 
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 4.4 Factors influencing enrolment into the PMTCT programme 
Table 4.3 presents factors that influenced pregnant women to participate in PMTCT 
programme. Thirty-eight (23.6%) of these women who participated in the study were put 
in PMTCT programme in this pregnancy, and this also represents the HIV prevalence rate 
among the study participants. Six of the 161 participants whose data on PMTCT were 
captured did not test for some reasons, mainly because they were scared of knowing their 
status. VCT uptake among the study participants was about 96.9%. The majority of 
women put in the PMTCT program were happy with hospital staff (89.5%), organization 
of the programme (97.4%), and drug supply (81.6%). Five (13.2%) of pregnant women 
put in PMTCT programme experienced drug side effect.  Twenty-seven (84%) of these 
women who were in the programme, said safety of their unborn baby motivated them to 
enrol in the programme. Only one of the participants recalled she did not enrol for 
PMTCT and knowing she tested HIV+ve. Six others were of unknown status and unsure 
of PMTCT treatment or not. PMTCT uptake can therefore be estimated to be between 38 
of 45 (84.4%) and 38 of 39 (97.4%) of HIV+ve participants.  
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 Table 4.3: Factors influencing enrolment into the PMTCT programme among HIV-
infected postnatal women 
 No % 
Were you put on this programme in this pregnancy? 
Yes   38 23.5 
No 124 76.5 
                                                                Unknown     7  
   
Are you happy with programme in the following areas? 
Hospital Staff   
Yes 34 89.5 
No  4 10.5 
Organization of the programme   
Yes 37 97.4 
No  1  2.6 
Drug supply   
Yes 31 81.6 
No  7  18.4 
Experience drug side effect   
Yes 5 13.2 
No 33 86.8 
  
What motivated you to enroll in PMTCT program? 
Safety of the baby 27 71.1 
Partner  1 2.6 
Self  2 5.3 
Not sure of everything  7 18.4 
Need treatment  1 2.6 
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 4.5 Attitudes, beliefs and practice of PMTCT among participants 
The majority 111(68.9%) of women said they did not participate in PMTCT programme 
because they tested negative. Six (3.7%) of the participants did not test. VCT uptake 
among those whose data on VCT were captured had been estimated at 96.9%. Of those 
who did not test, four (66.7%) said they were scared of knowing their status and afraid of 
social stigma, one (16.7%) did not believe in HIV, and one (16.7%) did not know how to 
go about it.  None of the six who did not test had approached any health worker for help. 
Most (61.7%) of the participants said they discussed PMTCT with friends and/or relatives 
(Table 4.4). 
 
Table 4.4: Attitudes, beliefs and practice of PMTCT among participants  
 No % 
Reason for not enrolled in a program   
I didn’t test   6  3.7 
Test –ve 111 68.9 
Scared of side effect   1  0.6 
Others   6  3.7 
      VCT uptake among Participants        156    96.9 
   
If didn’t test, why?   
Don’t believe 1 16.7 
Don’t know how to go about it 1 16.7 
Scared of knowing my status 3 50.0 
Social stigma 1 16.7 
  
For reason given above, have you 
approached health worker for help? 
  
No 6 100.0 
  
Discussed PMTCT with friends/relatives   
Yes 100 61.7 
No  62 38.3 
 
This table also highlights the factors influencing VCT uptake among the participants. 
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4.6 PMTCT programme by selected demographics 
An attempt was made with statistical analysis to determine the relationship between some 
selected demographic variables of the participants and VCT uptake and PMTCT uptake.  
Significant association was found for age group (χ2 =11.0654, df 2, p-value = 0.0114); 
Women in the age group 20-29years are more likely to accept VCT and possibly enrol for 
PMTCT than women in the other age groups. No significant association was found for 
marital status (χ2 = 1.1669, df 2, p-value = 0.5580); and whether the woman lived with 
her partner or not (χ2 corrected (Yates) =2.8651, Fisher exact p-value = 0.445681228). 
 
 
 
Table 4.5: PMTCT program by selected demographics 
HIV-uninfected 
N=124 
HIV-infected N=38 Demographic  
variables 
No % No % 
Age group     
<20 30 24.2  1  2.6 
20-29 56 45.1 26 68.4 
30-39 34 27.4 10 26.3 
≥40  4  3.2  1  2.6 
    
Marital Status     
Single 82 66.1 22 57.9 
Married 42 33.9 16 42.1 
    
Live with a partner     
Yes 61 49.2 25 65.8 
No 63 50.8 13 34.2 
    
*Attended Antenatal 
care 
    
Yes 122 97.6 38 100.0 
No   3  2.4  0   0.0 
*Antenatal attendance is the gateway to PMTCT. 
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 Total no of 
women 
interviewed 
=169
Not aware of PMTCT 
= 8 (4.70%) 
Aware of PMTCT  
   =161 (95.30%) 
YES to VCT=155 
(96.90%)
NO to VCT = 6        
(3.10%)
Received test results.  
Tested –ve = 110 (70.97%) 
Received test results. 
Tested +ve =38(24.52%) 
Did not receive test 
results =7 (4.52%)
Figure 4.1 PMTCT CASCADE OF RESULTS 
 
All HIV+ve women identified received intervention as per national PMTCT protocol.   
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 CHAPTER 5 
 
 
DISCUSSION 
 
Worldwide more than 2 million HIV-infected women give birth annually but only 9% of 
them receive PMTCT intervention18. PMTCT uptake has however recorded a lot of 
improvement in the Southern Africa, where HIV prevalence is widespread among 
pregnant women, with Botswana said to be taking the lead, recording less than 4% HIV 
infections in the newborn, a rate comparable with USA and Western Europe33. 
 
As noted in the introduction, the result of this study showed an unexpectedly high uptake 
of VCT (96.3%) among participants, and similarly high average PMTCT uptake, 
(90.9%), among HIV-infected participants. Several studies27,28 have reported similar 
findings, and nationally the average VCT uptake of 70% and PMTCT uptake of 60% had 
been recorded29  
    
5.1 Factors influencing enrolment into PMTCT programme among participants  
Factors that positively influenced enrolment into the PMTCT programme in this study are 
displayed on Table 4.3. These are discussed further below: 
  
5.1.1. Government commitment 
The efforts of health institutions implementing clear and well defined government policy 
and guidelines on PMTCT have turned around the initial problems associated with VCT 
uptake and PMTCT enrolment among pregnant women. In a study in Vietnam34, a well 
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 resourced setting, lack of knowledge and information due to poor counseling, gaps in 
PMTCT services and fear of stigma and discrimination were identified as most important 
barriers to uptake of PMTCT programme. Operational guidelines on PMTCT in Vietnam 
were not available. Other Asian nations reported same problem19,35  
 
It would appear that governments in the sub-Saharan Africa have come to terms with the 
realities of the HIV problems and are facing up to it squarely with all the assistance and 
resources available. Unlike in Vietnam where accessibility to PMTCT services was about 
44% due to various reasons, accessibility in South Africa “is 100% in all public hospital 
and more than 90% in primary health care centres countrywide”29. And so it is in 
Botswana, Zimbabwe and others.  
 
5.1.2 Awareness and Knowledge of PMTCT processes 
High level of awareness and good knowledge of the processes and expected outcome had 
empowered many of the participants in this study to take a bold step in accepting VCT 
and those who tested positive going ahead to enrol into the PMTCT programme against 
all odds. Most women in the Vietnam study were not aware that medication could prevent 
MTCT. . “In multivariate analysis, factors associated with having an HIV test included 
being interviewed at an urban site, having a high PMTCT knowledge score, knowing 
someone receiving PMTCT or ART and having a partner who had been tested for 
HIV.”27 
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 5.1.3 Hospital staff  
Painter et al36 (10BT2-6) presented the reasons for women not participating in a PMTCT 
programme in Abidjan. This qualitative study, conducted on a sample of 27 women, 
included interviews of non-participating women. Among the reasons, 70% cited 
difficulties with clinical staff or procedures and 48% did not believe test results. 
 
Health care workers especially the Nurses in the antenatal clinics made the most 
contribution to the awareness and high level of knowledge among participants in this 
study. Continuous training and capacitating these health workers thus become paramount. 
Most of the participants enrolled in the PMTCT in this study were happy with the 
hospital staff. 
 
5.1.4 Mass Media 
 The contribution of mass media is also acknowledged in this study as have other studies. 
In a retrospective study of local language radio programme32 – The Abstinence Be 
faithful for Youth (ABY), in Uganda, all the VCT records reviewed in all three health 
centres, showed an increase in number of VCT clients from 777 between November 2004 
and August 2005 to 915 between September 2005 and August 2006. A year on year 
increase of 15%. PMTCT records showed an increase from 520 to 1542 during the same 
period. Service providers attributed the increase to the ABY programme. “The radio 
programme helped to remove the fear of testing. You know people naturally used to fear 
testing for HIV” concluded the officer in charge of PMTCT in Kapchorwa hospital. 
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 5.1.5 Organization of the programme  
Participants enrolled in the PMTCT programme mostly agreed the programme was well 
organized. Patients’ flow from one service point to the other was explored and vast 
majority of them (97.4%) were happy with the organization. 
 
 5.1.6 Availability of ARV medication  
Availability of ARV’s at no cost to the participant was one major factor that has 
positively influenced enrolment into the programme. Again in the Vietnam study “one 
reason for the disappointing record was that ARV was not consistently available. Often a 
single dose of NVP for women who were tested only at the time of delivery was lacking”. 
 
5.1.7 Side effects of ARVs’  
It is good news that majority of participants (86.8%), enrolled in the PMTCT programme 
did not experience major side effects from ARVs’. Side effects are always a major 
setback. As noted in chapter 1 under introduction, the prevalence of maternal anaemia has 
reduced the acceptability and safety of AZT. Side effects of ARV was one major concern 
for government in South Africa to prevaricate on ARV roll out for PMTCT and HIV 
treatment, until the Constitutional court ruled against government’s position in 2002. 
 
5.1.8 Safety of baby  
This was one strong motivator for enrolment into the programme among participants in 
this study. This factor had also been found consistently a strong motivator in some other 
studies  
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 5.2 Factors influencing uptake of VCT among participants 
Uptake of VCT is regarded as the entry point into the PMTCT programme. Therefore 
factors which influence uptake of VCT will also directly influence enrolment into the 
PMTCT programme. 
 
5.2.1 Fear of stigma and discrimination 
Majority of those who did not test were scared of knowing their status for fear of stigma 
and discrimination indicating that this factor is still a major barrier to uptake of VCT and 
PMTCT. Aside its incurable and debilitating nature, the greatest problem of HIV/AIDS 
which follows from this nature, is the stigma and discrimination associated with it. It has 
consistently shown its face in every study and discussions around HIV/AIDS. Every other 
reason for low uptake of VCT either directly or indirectly derived from this. Other 
incurable and debilitating diseases like diabetes mellitus have been accepted by the 
society. This problem will linger on for a long while, and strategies aimed at 
destigmatizing persons living with HIV and AIDS should be further explored and 
strengthened.  
    
5.2.2 Quality of counselling 
Uptake of VCT in most sub-Saharan Africa correllates well with PMTCT uptake. The 
study in Vietnam where VCT uptake of 85% strongly contrasted PMTCT uptake of 20%, 
highlighted the missing link of knowledge and information from high quality counselling 
on PMTCT. The counselling in PMTCT should specifically address the fears and needs 
of HIV positive pregnant women and the support available to them and their unborn 
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 children as distinct from routine VCT services.  In a study of factors influencing teen 
mothers’ enrolment and participation in PMTCT in Limpopo Province37, client-
counsellor dynamics during pre-test counselling were pivotal in determining uptake and 
participation in PMTCT programme and counsellor profile strongly influenced the nature 
of the interaction. 
 
5.2.3 Maternal age-group  
Significant association was found for VCT uptake and maternal age-group. Mothers in 
the age-group 20-29 were more likely to accept VCT and possibly enrol for the PMTCT 
than mothers in the other age groups (p=0.0114). This age-group also represented the 
modal age-group in this study. Mothers in this age-group are more likely to be newly 
married with high hopes for the future. They perhaps would be more sexually-active than 
other age-groups, and perhaps more HIV-conscious than other age-groups.  The exact 
reason or reasons for this finding could not be ascertained and more studies on this will 
therefore be important. 
 
 
 
5.3 This study and others 
Most studies on PMTCT uptake have been done during the antenatal period and have 
tended to equate VCT uptake with PMTCT uptake. While there is a good correlation 
between VCT and PMTCT uptake, this is not always so. One study in Zambia38 found 
that  1/3 of patients given Nevirapine never ingested it. Also the study in Vietnam 
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 mentioned above is a good example. This study was carried out in the postnatal period, 
among post-partum women who were expected to have gone through major stages of the 
PMTCT programme (see fig.5.1), and therefore had a good knowledge and rich 
experience of the programme to share.  
The entire process is illustrated below.  
 
 
Fig.5.1. PMTCT Flow chart.  
(Reproduced from the article Prevention of mother-to-child transmission Worldwide) 
 
The actual uptake of PMTCT intervention can only more accurately be estimated in this 
period. 
 
The principles29 guiding the implementation of the policy and guidelines on PMTCT 
place the duty and responsibility on all health workers “to identify HIV positive women 
and their partners, HIV-exposed infants and HIV positive infants so that they can access 
HIV care”. While health workers may therefore be seen as carrying out their duties, it 
must still be practised within a human rights framework. The guidelines enjoin health 
workers to offer VCT repeatedly, at every visit – some sort of pressure on clients to take 
up HIV test. Botswana that had since made HIV counselling and testing (HCT) part of 
routine antenatal screening has overcome this dilemma, has recorded the greatest uptake 
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 of PMTCT and has been able to reduce MTCT to less than 4%, simply by making it a 
policy to include HCT as part of routine antenatal screening. No one seems to have been 
offended ever since.  
 
al 
 
hese concerns and others are some of what PMTCT counselling is supposed to address 
 
                                                                                                                                                                              
In the stages of behaviour change model39, participants were already past the stage of 
contemplation and were ready to change. It is now widespread knowledge that antenat
care encompasses VCT and PMTCT enrolment where necessary. Government only needs
to make the pronouncement as a matter of policy while at the same time emphasizes 
confidentiality of test results as much as possible. It will help them maintain this 
readiness to change and increase their confidence too. 
 
T
clearly as distinct from routine VCT services.   
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 CHAPTER 6 
CONCLUSIONS    AND RECOMMENDATIONS 
6.1 Conclusions 
pts had been made to study the factors that affected or were still 
 study 
 
he study took a 3-dmensional view of the factors – institutional, patient-related, and the 
he age participants ranged from 14to 41years, 63% of them unmarried, and 84% had 
n with 
 
In this study, attem
affecting uptake of voluntary counselling and enrolment into the programme of 
prevention of mother-to-child transmission of HIV among postnatal women. The
was conducted in the post-partum period, a period when pregnant women were supposed
to not only have learnt much about the programme but have actually experienced the 
programme at its different stages.  
 
T
environment or community. The study had been from the patient’s perspective since they 
were the ones at the centre, being influenced either positively or negatively by the other 
two broad categories of factors.  
 
T
education up to secondary school. About 60% had household income <R2500.00. 
Highlights of this study were very high uptake of VCT and high rates of satisfactio
the programme among HIV-infected women.   Vast majority, (>90%), of participants had 
good knowledge of the PMTCT programme. Antenatal HIV prevalence rate of 24.52% in 
this study compared well with an average of 28% in the previous 12months in the study 
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 centre. Women in the age-group 20-29 were more likely to accept VCT and enrol for 
PMTCT than in other age groups (p=0,0114)   
 
The positive steps taken by various governments in the sub-Saharan Africa, South Africa 
inclusive, were highlighted in this study. The provision of clear and well-defined policy 
guidelines and strong commitment to implementation of these guidelines have left the 
various health institutions with no other choice but to follow suit. Positive institutional 
factors have been largely responsible for the improvements recorded in the enrolment 
into the PMTCT programme in this study. The community which represents the patients’ 
immediate environment had either contributed negatively or none at all on positive 
disposition of pregnant women towards PMTCT.  
 
 
6.2 Recommendations  
The results of this study have shown that there was widespread knowledge of PMTCT 
among the participants. Many have come to term with the fact that antenatal attendees 
necessarily will be offered VCT as a possible entry point into the PMTCT programme. 
Only a little impetus is needed to instil confidence in the pregnant women to take up HIV 
testing.      
Training of more PMTCT counsellors including lay counsellors from within the 
community is recommended for its cost-effectiveness. 
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 Since PMTCT goes beyond administering ARV to mother and child, more studies on 
adherence to follow-up phase of the programme would help to consolidate on the 
improvements so far recorded.    
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 APPENDIX 1 
 
 
INTERVIEW QUESTIONNAIRE 
(Final version) 
 
Section 1:    
Demographic details: 
Where applicable please tick (√) in the following questions: 
 
1. How old are you? (What year were you 
born?)……………………………………………… 
 
2. Are you: Married □/ Single□/ Divorced□/ Widowed□/ 
 Others…….. 
 
3. Do you live with your partner?   Yes□/  No□ 
 
4. How many babies have you before this? 
…………………………………………………... 
 
5. Any miscarriages?    Yes□/  No□/  
             If Yes, how many? .................................... 
 
6. What is your highest level of education? What grade?.......... Matric □/
 Diploma□/ Degree□/ Postgraduate□/ Others (please 
state)……………………………………… 
 
7. If yes to question 3, what is your partner’s highest level of education?  What 
grade?.....   Matric □/ Diploma□/  Degree □/   Postgraduate□/   Others 
(please state)……………………… 
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 8. What is your total household income?       None (unemployed)           <R2, 
500□/ 
      R2, 501 – R5,000 □/      R5, 001 – R10, 000 □/      R10, 001 – R20, 000□/      
>R20, 000 □/ 
  
 
 
      
Section 2: 
1. Are you aware that there is a programme for prevention of mother to child 
transmission of HIV?      Yes□/    
 No□/ 
 
2. If yes how did you know about it? Prompts!!! Friend □/ Nurse□/ 
 Doctor□/ TV□/ Radio□/ Newspaper/Magazine □/ Partner□/
 Other □/(Please specify)…………….. 
 
3. What do you know about the programme?      
   Content of the programme 
¾ Voluntary counseling and testing  Yes□/  No□/ 
¾ Enrolment of HIV +ve mothers so that they can have adequate information 
about the programme and regular antenatal visits Yes□/  No□/ 
¾ Medication for mother and child  Yes□/  No□/ 
¾ Timing of medication    Yes□/  No□/ 
¾ Testing of the child at certain age  Yes□/  No□/ 
¾ Follow up of mother and child  Yes□/  No□/ 
 
4. Were you put on this programme in this pregnancy?  Yes□/  No□/. 
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 Questions 5 – 7 are for those who answered “Yes” to question 4. 
5. If yes, are you happy with the programme so far, particularly in the following 
areas? 
¾ With the……….  
¾ Hospital staff?    Yes□/  No□/  Don’t 
know□/ 
¾ Organization of the programme?  Yes□/  No□/  Don’t 
know□/ 
¾ Drug supply? (Is it always available) Yes□/  No□/  Don’t 
know□/ 
Have you experienced any serious side effects from the drugs?  
                                                                       Yes□/   No□/              Don’t 
know□/ 
¾ Any other thing you would like to comment on? 
……………………………………… 
 
 
6. That you are on the programme means that you chose to test and you tested 
positive, what motivated you to test?  Friend□/ Patient□/
 Partner□/ TV□/  Radio□/ 
 Newspaper/magazine□/ Doctor□/ Nurse□/ Others (please 
state)…………………. 
 
7. We also know that not all those who tested positive are subsequently enrolled into 
the programme, what motivated you to enroll? Please 
state………………………………………………………...... 
 
Question 8 – 10 are for those who answered “No” to question 4. 
      8. If ‘No’ to question 4, why were you not enrolled into the programme?  I did 
not test □/  Tested – ve□/  Scared of side effects□/ others please 
specify……………………….. 
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      9. If you did not test, why? Scared of knowing my status□/ Social 
stigma□/   didn’t know how to go about it □/ don’t believe in it□/ 
 others specify………………… 
 
     10. For the reasons given in 9 above, have you ever approached any health worker for 
help?         Yes□/  No□/ 
 
     11. Have you ever discussed PMTCT with your friend or relative who is pregnant? 
         Yes□/  No□/ 
 
     12. Is there anything you would like to 
add?.................................................................................. 
 
  
   
      Thank you. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 45
 APPENDIX 2 
 
 
PARTICIPANTS INFORMATION SHEET 
(Final version) 
 
Hello Madam, 
 
I am Dr. Joshua Ajewole, a general practitioner doing a research on the prevention of the 
spread of HIV, especially in the newborns. The study is for my Masters Degrees in 
Family Medicine of Wits Medical School, Johannesburg. I am asking Sister……………. 
to help me translate my discussion with you in your mother tongue, for better 
understanding. 
 
We would like to use this medium to formally invite you to participate in the study. If 
you choose to participate, we would then spend a few minutes asking you questions on 
this topic. We are aware that some of the questions may touch on your privacy. If you are 
not comfortable with any question you don’t have to answer it. Also if you are not willing 
to participate in the study, you have a right to say so, and that will not affect the care 
being given to you by the doctors and nurses. You also have the right to withdraw your 
participation at any stage. Again, it will not affect your care in any way. 
 
Your name or that of any other participant is not in the questionnaire, and nobody’s name 
will be mentioned or published anywhere, at any stage, during the study. Even the name 
of this hospital will not be mentioned to anyone. All information gathered will be kept to 
ourselves, and will be used only for the purpose of this study. 
 
Permission for this study has been obtained from Human Research Ethics Committee of 
Wits, and other relevant bodies. 
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 For further information on this study, you can ask now or after leaving here, my contact 
telephone number is given at the bottom of this information sheet. 
 
Thank you. 
 
Dr. Olusesan J. Ajewole (MBBS. Lagos) 
082 839 0243 
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